Full Report

Format

Full Report
Summary (Text)
Summary (XML)

Send to:

Choose Destination

File
Clipboard
Collections

Grade 1 Diffuse Follicular Lymphoma

MedGen UID:: 437295
•Concept ID:: C2697518
•: Neoplastic Process

Definition

A follicular lymphoma with diffuse pattern characterized by the presence of 5 or less centroblasts per 40 high-power fields. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVGrade 1 Diffuse Follicular Lymphoma

B-cell lymphoma
- B-cell lymphoma
  - B-cell lymphoma
    - B-cell lymphoma
      - Follicular lymphoma
        Diffuse Follicular Lymphoma
        Grade 1 Diffuse Follicular Lymphoma

Professional guidelines

PubMed

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Follicular lymphoma: 2014 update on diagnosis and management.

Freedman A
Am J Hematol 2014 Apr;89(4):429-36. doi: 10.1002/ajh.23674. PMID: 24687887

See all (19)

Recent clinical studies

Etiology

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI
Lancet Oncol 2022 Aug;23(8):1066-1077. Epub 2022 Jul 12 doi: 10.1016/S1470-2045(22)00339-4. PMID: 35839786

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
Lancet 2020 Sep 19;396(10254):839-852. Epub 2020 Sep 1 doi: 10.1016/S0140-6736(20)31366-0. PMID: 32888407

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol 2019 Jan;20(1):31-42. Epub 2018 Dec 2 doi: 10.1016/S1470-2045(18)30864-7. PMID: 30518502 Free PMC Article

See all (241)

Diagnosis

Follicular lymphoma and marginal zone lymphoma: how many diseases?

Laurent C, Cook JR, Yoshino T, Quintanilla-Martinez L, Jaffe ES
Virchows Arch 2023 Jan;482(1):149-162. Epub 2022 Nov 17 doi: 10.1007/s00428-022-03432-2. PMID: 36394631 Free PMC Article

Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.

Tousseyn TA, King RL, Fend F, Feldman AL, Brousset P, Jaffe ES
Virchows Arch 2023 Jan;482(1):207-226. Epub 2022 Oct 24 doi: 10.1007/s00428-022-03427-z. PMID: 36274093

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Orbital lymphoma.

Olsen TG, Heegaard S
Surv Ophthalmol 2019 Jan-Feb;64(1):45-66. Epub 2018 Aug 23 doi: 10.1016/j.survophthal.2018.08.002. PMID: 30144455

See all (216)

Therapy

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY
N Engl J Med 2017 Dec 28;377(26):2531-2544. Epub 2017 Dec 10 doi: 10.1056/NEJMoa1707447. PMID: 29226797 Free PMC Article

See all (207)

Prognosis

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Orbital lymphoma.

Olsen TG, Heegaard S
Surv Ophthalmol 2019 Jan-Feb;64(1):45-66. Epub 2018 Aug 23 doi: 10.1016/j.survophthal.2018.08.002. PMID: 30144455

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

See all (229)

Clinical prediction guides

Follicular lymphoma: 2023 update on diagnosis and management.

Jacobsen E
Am J Hematol 2022 Dec;97(12):1638-1651. Epub 2022 Oct 18 doi: 10.1002/ajh.26737. PMID: 36255040

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963 Free PMC Article

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ
Lancet 2021 Sep 25;398(10306):1157-1169. Epub 2021 Sep 8 doi: 10.1016/S0140-6736(21)00889-8. PMID: 34508654

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857 Free PMC Article

Follicular lymphoma: 2020 update on diagnosis and management.

Freedman A, Jacobsen E
Am J Hematol 2020 Mar;95(3):316-327. Epub 2019 Dec 22 doi: 10.1002/ajh.25696. PMID: 31814159

See all (189)

Recent systematic reviews

Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.

Si T, Ma X, Zhu W, Zhou Y
Hematology 2023 Dec;28(1):2284047. Epub 2023 Nov 27 doi: 10.1080/16078454.2023.2284047. PMID: 38010876

Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R
Hematol Oncol 2021 Apr;39(2):215-221. Epub 2020 Dec 10 doi: 10.1002/hon.2828. PMID: 33252145

Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.

Wen KW, Fakhri B, Menke J, Ruiz-Cordero R, Gill RM, Ohgami RS
Ann Diagn Pathol 2020 Jun;46:151534. Epub 2020 May 15 doi: 10.1016/j.anndiagpath.2020.151534. PMID: 32473554

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.

Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW
Lancet Haematol 2020 Apr;7(4):e295-e308. Epub 2020 Mar 2 doi: 10.1016/S2352-3026(20)30031-4. PMID: 32135128

Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.

Wolach O, Bairey O, Lahav M
Medicine (Baltimore) 2010 Sep;89(5):308-318. doi: 10.1097/MD.0b013e3181f2caef. PMID: 20827108

See all (5)

MedGen

National Center for Biotechnology Information

Send to:

Grade 1 Diffuse Follicular Lymphoma

Definition

Term Hierarchy

Professional guidelines

PubMed

Recent clinical studies

Etiology

Diagnosis

Therapy

Prognosis

Clinical prediction guides

Recent systematic reviews

Supplemental Content

Table of contents

Practice guidelines

Related information

Recent activity